Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.28 in Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 37.78% year-over-year to -$0.28; the TTM value through Sep 2025 reached -$0.31, up 83.45%, while the annual FY2024 figure was -$1.58, 32.48% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.28 in Q2 2025 per FHTX's latest filing, up from -$0.3 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.26 in Q3 2024 and bottomed at -$0.77 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.56, with a median of -$0.62 recorded in 2021.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 78.28% in 2021, down 130.43% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.77 in 2021, then rose by 10.39% to -$0.69 in 2022, then grew by 17.39% to -$0.57 in 2023, then soared by 47.37% to -$0.3 in 2024, then increased by 6.67% to -$0.28 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.28 in Q2 2025, -$0.3 in Q4 2024, and -$0.26 in Q3 2024.